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Abstract
 Purpose—To explore whether, and to what extent, minor consent influences adolescent 
vaccine delivery in the United States.
 Methods—A telephone survey was completed by 263 professionals with responsibilities for 
adolescent health care and/or vaccination in 43 states. Measures included perceived frequency of 
unaccompanied minor visits and perceived likelihood of vaccine delivery to unaccompanied 
minors in hypothetical scenarios that varied by adolescent age, vaccine type, visit type, and 
clinical setting.
 Results—Among the 76 respondents most familiar with private primary care clinics, 47.1% 
reported perceptions that 17-year-old patients often present without a parent/legal guardian. 
Among the 104 respondents most familiar with public primary care clinics, 56.7% reported that 
17-year-old patients often present alone. In response to hypothetical scenarios, approximately 30% 
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of respondents familiar with private clinics and 50% of respondents familiar with public clinics 
reported perceptions that unaccompanied 17-year-old adolescents would not receive influenza, 
Tdap, or human papillomavirus vaccines during routine check-ups because they could not provide 
consent. Perceived likelihood of unaccompanied minors receiving vaccines when seen for 
confidential services in primary care, sexually transmitted disease, and Title X/family planning 
clinics varied significantly by vaccine type and clinical setting. On average, respondents reported 
that they would support minors having the ability to self-consent for vaccines at age 14.
 Conclusions—The inability of minors to consent for vaccines is likely one barrier to 
vaccination. Interventions to increase adolescent vaccination should consider strategies that 
increase the ability of unaccompanied minors, particularly older minors, to receive vaccines within 
the context of legal, ethical, and professional guidelines.
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There have been substantial changes in recommendations for routine vaccination among 
adolescents, including new recommendations for pertussis (TdaP), meningococcal (MCV4), 
human papillomavirus (HPV), and influenza vaccines [1,2]. Although the proportion of 
adolescents who receive recommended vaccines has steadily increased, levels of adolescent 
vaccination coverage are suboptimal and below levels of coverage for recommended 
vaccines among young children [3–6]. In 2011, vaccination coverage among adolescents 
ages 13–17 was 78% for Tdap and 71% for MCV4; 53% of females in this age group 
received at least one HPV vaccination and only 35% completed the three-dose vaccine series 
[7]. In contrast, at least 90% of children 19–35 months of age have received at least one dose 
of measles/mumps/rubella and varicella vaccine, as well as three doses of DTP/DT/Tdap, 
Haemophilus influenza type B, hepatitis B, and pneumococcal conjugate vaccine [8,9].
Multiple barriers to high rates of adolescent vaccination coverage have been described [10–
14], but whether issues related to minor consent may act as a barrier to receipt of vaccines is 
not known [15,16]. During adolescence, there are circumstances in which minors may be 
permitted to provide their own informed consent for health care services and parental 
consent is not required. The informed consent requirements for minors vary by state and are 
guided by a combination of state and federal laws, the mature minor doctrine, and 
recommendations of professional organizations [17–23]. Circumstances in which a minor 
may consent for his or her own care typically include when a minor is emancipated or has 
another “status” that supports independent consent (e.g., married, homeless), or is receiving 
services related to sensitive health concerns (e.g., sexually transmitted diseases [STDs], 
pregnancy prevention, pregnancy, substance use, or mental health issues). State laws are 
generally silent on the specific issues of minor consent and vaccination. In a few states, 
however, minor consent laws specifically allow minors to consent to services for the 
prevention (as well as diagnosis and treatment) of STDs [15,23]. These laws have been or 
could be interpreted to allow HPV vaccination based on a minor’s consent [15]. It is within 
this context of varying circumstances that practitioners make decisions about whether 
unaccompanied minors can provide their own consent to receive vaccinations.
Ford et al. Page 2













To better understand whether issues related to minor consent may act as a barrier to 
adolescent vaccination, we investigate perceived frequency of unaccompanied minor visits 
to health care settings, and providers’ perceptions of the extent to which minor consent 
issues influence delivery of vaccine by adolescent age, vaccine type, and clinical setting. 
Finally, we assessed whether key stakeholders would support minor consent for vaccines.
 Methods
We conducted a telephone interview survey of professionals across the United States with 
direct responsibilities related to adolescent health care or vaccinations. The study was 
approved by our Institutional Review Board.
 Survey sample
In this exploratory study, we were interested in the perspective of representatives from 
diverse clinic settings in which adolescent vaccines are delivered. Adolescent vaccines are 
delivered in public and private primary care clinics, STD clinics, and family planning 
clinics; furthermore, immunization program managers may be involved with vaccine 
delivery programs in all sites. We therefore used a purposive sampling design to survey 
medical providers familiar with adolescent vaccine practices in public or private health care 
settings, immunization program managers, STD program managers, and Title X/family 
planning program managers.
We did not aim for a representative sample of providers. We intended to interview four 
medical providers in each state. Names of medical providers familiar with adolescent 
vaccine practices were solicited from the leadership of state American Academy of 
Pediatrics chapters and regional Society for Adolescent Health and Medicine chapters; 
nondiscriminative snowball sampling allowed us to contact multiple potential participants.
For public health officials, we intended to interview one immunization, one STD, and one 
Title X/family planning program manager in each Centers for Disease Control and 
Prevention–recognized state and jurisdiction. There are five jurisdictions for immunization 
programs, six jurisdictions for STD programs, and one jurisdiction for Title X/family 
planning. Lists of immunization and STD program managers were provided by the Centers 
for Disease Control and Prevention. Contact information for Title X grantees was obtained 
from the Office of Population Affairs. Program managers were allowed to designate proxy 
respondents if they felt a staff member would be more familiar with vaccine practices in 
their clinic settings.
Potential study participants were solicited via email with limited telephone and facsimile 
follow-up; contact information for those interested in participating was provided to the 
University of North Carolina Survey Research Unit. A minimum of 12 telephone call 
attempts were made by the Survey Research Unit. Respondents who provided verbal 
informed consent were interviewed upon initial contact when possible; otherwise, 
appointment times accommodated respondents’ schedules. Respondents were not 
compensated.
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Data collection occurred between February and April 2009 using Blaise computer-assisted 
interviewing system. After respondents were queried about demographic characteristics, 
interviewers determined whether respondents were most familiar with vaccine practices in 
private primary care, public primary care, STD, or Title X/family planning clinics in their 
state; skip patterns in the survey directed respondents to questions relevant to the settings 
with which they were most familiar. Respondents were instructed that the term “parent” 
would be used to represent “parent or legal guardian” for the entire survey, and that the 
survey was intended to assess vaccine practices for cognitively normal adolescents. On 
average, each interview lasted 20 minutes.
 Measures
Sociodemographic characteristics included gender, age, and professional role (medical 
provider; immunization, STD, or Title X/family planning program manager).
Perceived frequency of unaccompanied minor visits in public and private primary care 
clinics was measured by asking respondents their perception of how often 17-, 15-, and 12-
year-old adolescents visit primary care clinics for medical care without a parent in the 
building. Response options included often, sometimes, rarely, never, and don’t know.
Extent to which minor consent issues influence delivery of vaccine was investigated by a 
series of hypothetical scenarios. Respondents were asked how likely it would be for 
adolescents of differing ages (e.g., 17, 15, 12 years) to be vaccinated in their state within the 
context of hypothetical scenarios during which an adolescent was medically eligible, the 
specific vaccine (e.g., influenza, Tdap, HPV) was available in the clinical site at no cost, the 
adolescent agreed to be vaccinated, and a parent was not available even by phone to provide 
consent; response options included all, most, or some or none of the time. Respondents 
received scenarios linked to the clinical site with which they were most familiar. Because 
adolescents may seek routine or confidential health care within primary care clinics (which 
may influence clinicians’ behaviors in terms of delivery of vaccine), respondents familiar 
with primary care clinics were asked to respond to scenarios representing each of these 
situations separately. In scenarios for respondents most familiar with STD and Title X/
family planning clinics, we used adolescents presenting alone for STD (or family planning) 
services, and clarified that there was no known or suspected history of sexual abuse.
Age at which respondents would support minor consent for influenza, Tdap, and HPV 
vaccines was measured by the following: “At what age would you support efforts to allow 
minors to consent for their own (specifically named) vaccinations?” Response options were 
listed as younger than 11, by 1-year intervals between 11 and 21 years of age, and older than 
21.
 Analysis
Descriptive statistics identified the sociodemographic characteristics of respondents and 
their responses to the survey questions. Generalized estimating equations for the generalized 
linear model were used to estimate difference in distribution of perceived visit frequency by 
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age group and clinical setting while controlling for correlated responses by individuals. For 
each scenario presented, response categories representing the respondents’ perceived 
likelihood of the minor receiving each vaccine measured on a 5-point Likert scale were 
collapsed to a dichotomous response of none of the time versus all, most, or some of the 
time; don’t know and refuse responses were recoded as missing. We tested for three issues 
across scenarios: (1) likelihood of receiving different vaccines within each age group; (2) 
likelihood of receiving a specific vaccine across different age groups; and (3) likelihood of 
receiving a specific vaccine at a certain age by type of primary care sought (e.g., routine or 
confidential). Again, generalized estimating equations were used to estimate differences 
across scenarios while controlling for correlated responses. For each comparison, a score test 
was used to test the overall significance, followed by pairwise comparisons. Mean age of 
support for minor consent was calculated based on frequency distributions after recoding 
“younger than age 11” to age 10. Statistical tests were found significant at p < .05. All 
analyses were performed in SAS v.9.2 (SAS Institute Inc., Cary, NC).
 Results
 Sample
The sampling plan called for interviews of 366 professionals. Using referral sampling 
techniques, more than 800 e-mails were sent soliciting participation and/or referrals and 287 
professionals responded with interest in participating. Interviews were completed by 263 
participants in 43 states.
Most respondents were female (69.2%), the parent of a current or former adolescent 
(68.4%), and provided some direct clinical care (74.1%); their mean age was 50 years (range 
26–79). The largest professional group was medical providers (n = 130, 49.4%), who were 
evenly divided between those who reported that they were most familiar with private versus 
public clinic settings. Public health professionals from state or jurisdiction immunization (n 
= 52/55), STD (n = 42/56), and Title X/family planning (n = 39/51) programs made up the 
remaining 50.6% respondents. On average, respondents reported 6–10 years of experience in 
their current position, and those with direct clinical care reported 16–20 years of clinical 
experience.
 Perceived frequency of unaccompanied minor adolescent visits to primary care clinics
Seventy-six (28.9%) of all respondents reported they were most familiar with private 
primary care clinics. Nearly half (47.1%) of these respondents reported that 17-year-old 
patients often present for care without a parent in the building, and 47.1% reported that they 
sometimes present alone (Table 1). The distribution of perceived frequency of 
unaccompanied visits varied significantly by age of adolescent (p < .001). The vast majority 
(88.9%) reported that 12-year-old patients rarely or never seek care in private primary care 
clinics without the presence of a parent or guardian.
A total of 104 (39.5%) respondents reported that they were most familiar with public 
primary care clinics. When these respondents were asked about 17-year-old patients, 56.7% 
reported that they often present for care without a parent in the building and 30.9% reported 
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that they sometimes present alone (Table 1). Perceived likelihood of unaccompanied minors 
presenting for care varied significantly by age of adolescent (p < .001). The majority 
(66.3%) reported that 12-year-old patients rarely or never seek care in public primary care 
clinics alone.
 Private primary care clinics, minor consent, and vaccine delivery
Respondents’ most familiar with private primary care clinics (n = 76) were asked in 
hypothetical scenarios the likelihood that patients of differing ages (17, 15, 12) would be 
vaccinated in their state if the patient was medically eligible for a specific vaccine 
(influenza, Tdap, HPV), which was available on site at no cost, and a parent was not 
available even by phone for consent. Approximately 30% of respondents reported that 17-
year-old patients seen for a routine check-up and found to be eligible for HPV, influenza, 
and Tdap vaccines would not receive the respective vaccinations if a parent was not present 
(Figure 1A). The proportions of respondents reporting an unaccompanied adolescent would 
not receive vaccines increased as adolescent age decreased (p < .01), although there was 
variation by vaccine type. Seventy-three percent of respondents reported that 
unaccompanied 12-year-old patients would not receive HPV vaccine, whereas 56.0% 
reported that they would not receive influenza or Tdap (p < .01).
When queried about hypothetical scenarios during which an adolescent presented to a 
private primary care clinic requesting confidential STD testing, approximately 40% of 
respondents reported that 17-year-old patients presenting alone would not receive HPV, 
influenza, or Tdap even if they were medically eligible and free vaccines were available 
(Figure 1B). As with the scenario for routine visits, the proportions of respondents reporting 
an unaccompanied minor would not receive vaccines increased as adolescent age decreased 
(p < .05).
Respondents reported that 15- and 17-year-old unaccompanied adolescents seeking 
confidential services in private primary care clinics were less likely to receive Tdap and 
influenza vaccines than if they were seeking routine care (p = .05); reason for visit did not 
influence likelihood of receiving HPV.
 Public primary care clinics, minor consent, and vaccine delivery
When respondents most familiar with public primary care clinics (n = 104) responded to 
hypothetical scenarios, 48%–57% reported that unaccompanied 17-year-old patients seen for 
a routine check-up and found to be eligible for HPV, influenza, and Tdap vaccines would not 
receive any of these vaccinations (Figure 2A). The proportions of respondents reporting an 
adolescent would not receive vaccines if they were at the clinic without a parent increased as 
adolescent age decreased (p < .05), and approximately 67% reported that unaccompanied 
12-year-old patients would not receive any vaccines. The only variation by vaccine type was 
at age 17, when respondents reported adolescents were significantly less likely to receive 
influenza as compared to HPV vaccine (p = .01).
A difference in pattern was noted when respondents were asked about unaccompanied 
adolescents presenting to public primary care clinics for confidential STD testing (Figure 
2B). In this scenario, the absence of a parent was less of a barrier to receiving HPV vaccine 
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as compared with receiving influenza or Tdap vaccine (p < .001). Nonetheless, 34.0% of 17-
year-old and 53.6% of 12-year-old unaccompanied patients would not receive HPV vaccine.
 STD clinics
In response to scenarios that provided the hypothetical context that all vaccines were 
available on site and free, STD clinic program managers and those respondents most 
familiar with practices in STD clinics were asked to report the likelihood that 
unaccompanied minors of varying ages presenting for STD services would receive HPV, 
hepatitis B, influenza, and Tdap vaccines if they were found to be medically eligible. A 
significantly higher proportion of respondents reported a 12-year-old adolescent would not 
receive vaccines if they were at the clinic without a parent compared with 15 or 17 year olds 
(p < .05) (Figure 3). Regardless of the age of the patient, respondents were significantly less 
likely to report that influenza and Tdap vaccines would be administered to unaccompanied 
minors when compared with hepatitis B and HPV vaccines (p < .05).
 Title X/family planning clinics
Similarly, Title X/family planning program managers and those respondents most familiar 
with practices in family planning clinics were asked to report the likelihood that 
unaccompanied minors of varying ages presenting for family planning services in a 
hypothetical scenario would receive vaccines if they were found to be medically eligible for 
free, available vaccines. The proportion of respondents who reported that 12-, 15-, and 17-
year-old patients would not likely receive hepatitis B or HPV vaccine ranged from 46.0% to 
29.7% (Figure 4). The proportion of respondents who reported that 12-, 15-, and 17-year-old 
patients would not likely receive influenza or Tdap vaccine ranged from 63.2% to 54.1%. 
Respondents reported that 15- and 17-year-old patients were significantly less likely to 
receive influenza and Tdap as compared with HPV and hepatitis B vaccines (p < .01).
 Age of support for minor consent
When respondents were asked at what age they would support efforts to allow minors to 
consent for their own vaccinations, responses ranged from younger than 11 to 18 years for 
Tdap and influenza and 11–18 years for HPV. Respondents reported they would, on average, 
support efforts to allow minors to consent for their own vaccination at the following ages: 
13.8 (standard deviation [SD] 2.1) years old for HPV; 14.1 (SD 2.2) years old for influenza; 
14.3 (SD 2.2) years old for Tdap.
 Discussion
The majority of key stakeholders who participated in this study perceive that older minors 
sometimes or often present alone to primary care clinic settings. In response to hypothetical 
scenarios, they also report perceptions that many unaccompanied minors would not receive 
vaccinations even if they were due for vaccines, medically eligible, agreed to be vaccinated, 
and the vaccines were available at no cost. These results add to our understanding of whether 
and how the inability of minors to consent for vaccines may act as a barrier to adolescent 
vaccination, and suggest that this is an area that warrants further investigation.
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Perceptions that older adolescents are more likely than younger adolescents to visit clinic 
settings without their parents are not surprising. Older adolescents may be asked by parents 
to visit clinics alone (e.g., when parents have to work), and have the skills to use public or 
motor vehicle transportation. Older adolescents are also more likely to engage in sexual 
behaviors that place them at risk for STDs and pregnancy [24,25] and to seek health care for 
confidential services [26]. Interventions to increase adolescent vaccination rates may be 
strengthened by considering issues related to the ability of unaccompanied older minors to 
receive vaccines within the context of legal, ethical, and professional guidelines [15,16,23]. 
Younger minors visit clinic settings without a parent less frequently than older minors, 
although some do. Strategies developed to increase vaccination of older minors could be 
evaluated to determine their appropriateness for younger minors, depending on the setting 
and other circumstances.
Based on respondents’ perceptions of what would happen in hypothetical scenarios, there 
may be variation in the extent to which an unaccompanied minor’s ability to consent to 
vaccines influences vaccine delivery by vaccine type and clinical setting. For example, 
respondents perceived fewer minor consent–related barriers to receipt of HPV vaccine by 
unaccompanied minors of any age if they presented to public primary care clinics for 
confidential STD testing, STD clinics, or Title X/family planning clinics, both as compared 
with Tdap or influenza vaccine and with other clinical settings. This variation may be related 
to interpretation of state laws allowing minors to consent to STD-related health care in a way 
that permits minor consent for STD-related vaccination [23]. Variations in interpretation of 
state minor consent laws or implementation through clinic policies and procedures may also 
exist in private versus public settings. Based on respondents’ perceptions, if unaccompanied 
17-year-old adolescents presented for routine care in private primary care clinics, one-third 
would not be able to get Tdap and influenza vaccines because they could not provide 
consent. If same-aged adolescents presented to public primary care, STD, or Title X/family 
planning clinics, respondents reported at least half would not be able to receive these 
vaccines (even if available free) because they could not consent. Strategies that all clinics 
use to be able to deliver vaccines to adolescents in the absence of the physical presence of a 
parent are worth exploring. These may include obtaining parental consent for routine care 
and/or vaccines in advance of actual visits or strategies to obtain real-time consent with use 
of new technology (e.g., text messaging).
Clearly, minor consent-related barriers must be placed within the context of many other 
potential barriers to adolescent vaccination [27]. Compared with younger children, 
adolescents use health care less frequently and therefore have fewer opportunities to receive 
vaccines [28,29], whether or not a parent is present. Approximately 20% of adolescents are 
disconnected from routine care [24], and it is particularly unfortunate to miss any 
opportunities to vaccinate these young people. Vaccines are not widely available in all 
primary care clinics, and specialized clinics such as STD and Title X/family planning clinics 
may only carry vaccines linked to reproductive health care. Vaccine costs can represent a 
substantial barrier to vaccination. Further research will be needed to more fully understand 
the extent to which minor consent issues influence actual vaccination practices and to place 
these issues within the context of multiple other barriers.
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Limitations to this study include a purposefully selected rather than a representative sample 
of medical providers, although we did achieve near saturation sampling for STD clinic, Title 
X/family planning, and immunization program manager subsamples. We did not collect 
reasons for refusal and are unable to determine how this may have affected our results. We 
assessed respondents’ perceptions of vaccine practices and used hypothetical scenarios in 
our study; perceptions and responses to hypothetical scenarios may not reflect actual 
practices. We did not collect data that allowed us to estimate actual frequencies or quantify 
our results, which would be an important component of future research. Furthermore, we did 
not ask about efforts that may be used to contact parents of unaccompanied minors to 
encourage vaccination at later dates.
Despite these limitations, our results represent an initial step toward understanding the 
potential specific influence of minor consent on adolescent vaccine delivery. Future research 
is needed to verify that minor consent is in fact a barrier to actual adolescent vaccine 
delivery and to quantify the extent to which this may be true. Our respondents reported that 
they, on average, would support efforts to allow minors to consent for their own vaccinations 
at approximately 14 years of age, but it is not clear whether this is appropriate to consider, if 
or under what conditions parents and adolescents might also be in support [30], or whether 
this would be an effective strategy for increasing adolescent vaccination. Finally, efforts to 
understand state minor consent laws and policies, existing practices and procedures used for 
implementing state laws, and their impact on adolescent vaccine delivery will need to 
continue.
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This exploratory research suggests older adolescents are frequently seen in clinic settings 
without parents or legal guardians. Interventions to increase adolescent vaccination 
should consider strategies that increase the ability of unaccompanied minors, particularly 
older minors, to receive vaccines within the context of legal, ethical, and professional 
guidelines.
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Proportion of respondents who reported that unaccompanied minors would not likely receive 
vaccine in private primary care clinics within the context of hypothetical scenarios, by 
reason for visit, age, and vaccine (n = 76).a (A) Routine check-up.b,c (B) Confidential 
sexually transmitted disease (STD) testing.c aRespondents are those who reported they were 
most familiar with practices in private primary care clinic settings; for hypothetical 
scenarios, respondents were asked how likely it would be for cognitively normal adolescents 
of differing ages (e.g., 17, 15, 12 years) to be vaccinated in their state during a routine (or 
confidential) visit if medically eligible, the specific vaccine (e.g., influenza, Tdap, human 
papillomavirus [HPV]) was available in the clinical site at no cost, and a parent/legal 
guardian was not available even by phone for consent. bSignificant differences in likelihood 
of respondents reporting that a 12-year-old unaccompanied minor would receive HPV versus 
Tdap (p = .002), and HPV versus influenza (p < .001). cSignificant differences in likelihood 
of respondents reporting an unaccompanied minor would receive each vaccine by age (12 vs. 
15; 15 vs. 17; and 12 vs. 17; all p < .05).
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Proportion of respondents who reported that unaccompanied minors would not likely receive 
vaccine in public primary care clinics within the context of hypothetical scenarios, by reason 
for visit, age, and vaccine (n = 104).a (A) Routine check-up.b,c (B) Confidential sexually 
transmitted disease (STD) testing.c,d aRespondents are those who reported they were most 
familiar with practices in public primary care clinic settings; for hypothetical scenarios, 
respondents were asked how likely it would be for cognitively normal adolescents of 
differing ages (e.g., 17, 15, 12 years) to be vaccinated in their state during a routine (or 
confidential) visit if medically eligible, the specific vaccine (e.g., influenza, Tdap, human 
papillomavirus [HPV]) was available in the clinical site at no cost, and a parent/legal 
guardian was not available even by phone for consent. bSignificant differences in likelihood 
of respondents reporting that a 17-year-old unaccompanied minor would receive HPV versus 
influenza (p = .01). cSignificant differences in likelihood of respondents reporting an 
unaccompanied minor would receive each vaccine by age (12 vs. 15; 15 vs. 17; and 12 vs. 
17; all p < .05). dSignificant differences in likelihood of respondents reporting that an 
unaccompanied minor at each age (12, 15, and 17) would receive HPV versus influenza, and 
HPV versus Tdap (p < .001).
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Proportion of respondents who reported that unaccompanied minors would not likely receive 
vaccine in sexually transmitted disease (STD) clinics within the context of hypothetical 
scenarios, by age and vaccine (n = 40).a,b,c aRespondents included STD program managers 
and those who reported they were most familiar with practices in STD clinics; for 
hypothetical scenarios, respondents were asked how likely it would be for cognitively 
normal adolescents of differing ages (e.g., 17, 15, 12 years) presenting for STD services to 
be vaccinated in their state if the adolescent was medically eligible, the specific vaccine 
(e.g., influenza, Tdap, human papillomavirus [HPV], hepatitis [Hep] B) was available in the 
clinic at no cost, and a parent was not available even by phone for consent. bSignificant 
differences in likelihood of respondents reporting that a 12-year-old unaccompanied minor 
would receive HPV versus Tdap, HPV versus influenza, Hep B versus Tdap, Hep B versus 
influenza (p < .05); Significant differences in likelihood of respondents reporting that 15- 
and 17-year-old unaccompanied minors would receive HPV versus Tdap, HPV versus 
influenza, Hep B versus Tdap, Hep B versus influenza (p < .01). cSignificant differences in 
likelihood of respondents reporting an unaccompanied minor would receive HPV or Heb B 
vaccine by age groups 12 versus 15, and 12 versus 17 (p < .01) and for Tdap p < .05.
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Proportion of respondents who reported unaccompanied minors would not likely receive 
vaccine in Title X/family planning clinics within the context of hypothetical scenarios, by 
age and vaccine (n = 38).a,b aRespondents include Title X/family planning program 
managers and those who reported they were most familiar with practices in these clinic 
settings; for hypothetical scenarios, respondents were asked how likely it would be for 
cognitively normal adolescents of differing ages (e.g., 17, 15, 12 years) presenting for family 
planning services to be vaccinated in their state if the adolescent was medically eligible, the 
specific vaccine (e.g. influenza, Tdap, human papillomavirus [HPV], hepatitis [Hep] B) was 
available in the clinic at no cost, and a parent was not available even by phone for 
consent. bSignificant differences in likelihood of respondents reporting that 15- and 17-year-
old unaccompanied minor would receive HPV versus Tdap, HPV versus influenza, Hep B 
versus Tdap, Hep B versus influenza (p < 001).
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Table 1
Respondents’ perceptions of the frequency of minors presenting alone to private and public primary care 
clinics, by age
Clinical setting 12 year olds 15 year olds 17 year olds
Number (%) Number (%) Number (%)
Private primary care (n = 76)a
 Often seeks care alone 1 (1.4) 8 (11.4) 33 (47.1)b
 Sometimes seeks care alone 7 (9.7) 32 (45.7) 33 (47.1)
 Rarely/never seeks care alone 64 (88.9) 30 (42.9) 4 (5.7)
 Missing/unknown 4 6 6
Public primary care (n = 104)a
 Often seeks care alone 8 (8.2) 26 (26.8) 55 (56.7)b
 Sometimes seeks care alone 25 (25.5) 44 (45.4) 30 (30.9)
 Rarely/never seeks care alone 65 (66.3) 27 (27.8) 12 (12.4)
 Missing/unknown 6 7 7
a
Number of respondents most familiar with specified clinic setting.
b
Significant difference (p < .001) in distribution of frequencies reported across all age groups for clinic setting (i.e., 12 vs. 15; 12 vs. 17; and 15 vs. 
17).
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